|
$7,500,000
|
To provide general operating support.
|
2021 - 2024
|
DAF
|
|
$21,666,892
|
To support the Institute for Clinical and Economic Review research that provides independent analyses of the comparative cost effectiveness for newly-introduced pharmaceutical drugs.
|
2017 - 2021
|
LJAF
|
|
$5,232,002
|
To produce Institute for Clinical and Economic Review reports on new drugs that include information about a drug's comparative effectiveness, cost effectiveness, and potential budget impact.
|
2015 - 2017
|
LJAF
|
